Manual lymphatic drainage (MLD) is frequently applied in physiotherapy to manage lymphedema and postoperative swelling. Despite its widespread clinical use, uncertainty remains regarding its additional benefit beyond established treatments such as compression therapy and exercise. Recent research increasingly evaluates MLD within multimodal treatment frameworks rather than as a standalone intervention, necessitating an updated evidence-based synthesis.
- OPEN ACCESS ARTICLE - PUBLISHED 2026
CLINICAL EFFECTIVENESS OF MANUAL LYMPHATIC DRAINAGE: AN EVIDENCE-BASED REVIEW OF ITS ROLE IN EDEMA AND LYMPHEDEMA MANAGEMENT.
Author:
Tobias Giesen | DPT (USA), MSc SEM (UK), BSc PT (NL)
Independent Researcher in Physiotherapy and Sports Medicine
Germany
Abstract:
Introduction: Manual lymphatic drainage (MLD) is frequently applied in physiotherapy to manage lymphedema and postoperative swelling. Despite its widespread clinical use, uncertainty remains regarding its additional benefit beyond established treatments such as compression therapy and exercise. Recent research increasingly evaluates MLD within multimodal treatment frameworks rather than as a standalone intervention, necessitating an updated evidence-based synthesis.
Methods: A narrative integrative review of peer-reviewed literature published between 2016 and 2025 was conducted using PubMed, Scopus, Web of Science, and Cochrane databases. Randomized controlled trials, systematic reviews, and consensus statements investigating MLD in adult populations were included. Outcomes examined comprised limb volume reduction, postoperative swelling, symptom relief, functional recovery, and quality of life. Evidence was synthesized qualitatively due to methodological heterogeneity across studies.
Results: Across chronic lymphedema and postoperative contexts, compression therapy and active rehabilitation remain the primary drivers of sustained edema reduction. The additional effect of MLD on objective swelling reduction was often modest when compared with optimized standard care. However, consistent improvements were observed in patient-reported outcomes such as discomfort, heaviness, and tissue tension. These benefits appear particularly relevant during early treatment phases or when pain limits tolerance to compression or exercise.
Discussion: The evidence suggests that MLD functions best as a supportive intervention within multimodal rehabilitation programs. While it may not substantially alter long-term volume outcomes, MLD can enhance patient comfort and potentially facilitate engagement with more effective active treatment strategies. Methodological limitations across studies continue to restrict definitive conclusions.
Conclusion: Manual lymphatic drainage should be applied selectively within comprehensive edema management rather than as a primary treatment strategy. Future research should standardize protocols and identify patient subgroups in which MLD provides meaningful clinical benefit.
Keywords: manual lymphatic drainage; lymphedema; edema management; complex decongestive therapy; physiotherapy; postoperative swelling; rehabilitation; compression therapy
This paper is an independent academic publication in the field of Physiotherapy Science and Sports Medicine. The author declares no institutional affiliation and no conflicts of interest.
Introduction
Manual lymphatic drainage (MLD) sits in a curious place in modern physiotherapy: it is widely taught, widely billed, widely experienced as “helpful,” and yet its incremental clinical value beyond compression and exercise remains inconsistent across indications. This tension between tradition, plausibility, and measurable outcomes is exactly why MLD is worth revisiting with a strictly evidence-oriented lens. Over the last decade, research and consensus documents have steadily shifted the conversation away from “Does MLD work?” toward the more uncomfortable and clinically useful question: “For whom, for what endpoint, and compared to what does MLD add meaningful benefit?”
From a contemporary clinical taxonomy, MLD is most commonly positioned within Complex Decongestive Therapy (CDT), typically alongside compression (bandaging/garments), exercise, skin care, and education. This multimodal framing matters, because consensus guidance continues to describe CDT as the cornerstone of conservative lymphedema management, while also acknowledging variability in the contribution of individual components, including MLD (International Society of Lymphology [ISL], 2020). The ISL consensus document (2020) is particularly relevant for an evidence-based introduction because it reflects “real-world” standards of care while also implicitly admitting what randomized trials keep showing: compression and self-management tend to dominate long-term volume control, whereas the additive effect of MLD is harder to demonstrate reliably (ISL, 2020).
The most intensively studied indication for MLD is breast cancer-related lymphedema (BCRL). Here, the evidence base is large enough to be inconvenient: multiple controlled trials and meta-analyses exist, and they do not harmonize neatly into a single pro-MLD narrative. A pivotal multicentre randomized controlled trial reported that adding MLD to complete decongestive therapy did not yield further volume reduction compared with CDT alone in BCRL (Tambour et al., 2018). Meta-analytic work reinforces this mixed picture. A large meta-analysis of randomized trials concluded that MLD cannot significantly reduce or prevent lymphedema after breast cancer surgery overall, while also calling for better-designed trials and suggesting potential subgroup effects (Liang et al., 2020). More recent systematic review and metaanalysis efforts continue to evaluate whether outcomes such as pain, symptom burden, or quality of life show clearer signals than limb volume alone (Lin et al., 2022).
This is not a trivial methodological issue. “Edema reduction” is often treated as the primary endpoint, but lymphedema is not only a fluid-volume disorder. Tissue composition changes over time (e.g., fibrosis and adipose deposition), and symptoms such as heaviness, tightness, discomfort, and functional limitation frequently drive care seeking. If MLD exerts its most consistent effects via symptom modulation (for example, perceived heaviness or pain) rather than durable volume change, then trials designed around volume as the singular primary endpoint risk systematically underestimating clinically meaningful benefit. The literature increasingly reflects this broader framing, including work that compiles less-discussed effects and mechanisms of MLD rather than restricting evaluation to limb volume alone (Schingale et al., 2022). That said, sympathetic interpretations still have to contend with the fact that when compression is implemented well, the “room” for MLD to demonstrate added volume benefit narrows sharply, as seen in high-quality BCRL trials (Tambour et al., 2018).
A second key context is postoperative and post-traumatic swelling, where MLD is frequently prescribed under the assumption that it accelerates resorption of interstitial fluid and improves function. This is clinically intuitive, but the evidence again varies by surgery type, comparator, and dosage. In orthopedic contexts, randomized evidence exists showing that manual lymphatic techniques may not outperform other interventions when modern rehabilitation already includes early mobilization and compression. For example, a randomized controlled trial examined postoperative knee swelling with compression bandaging and MLD-related strategies (Bally et al., 2016). More recently, a prospective randomized trial compared a negative-pressure approach with MLD in postoperative swelling after total knee arthroplasty, illustrating how the field is actively benchmarking MLD against alternative edema-management technologies rather than assuming its primacy (Weber et al., 2025). Outside orthopedics, randomized clinical trial data also exist in dental surgery contexts, assessing outcomes such as edema, pain, and trismus after third molar extraction (Ulu et al., 2025). These studies are useful to an introduction because they demonstrate a broader trend: MLD is increasingly evaluated as one candidate among multiple swelling-management strategies, not a default standard.
A third, often-misunderstood area is lipedema. Modern consensus work emphasizes that lipedema is primarily a disorder of adipose tissue distribution and pain, not a lymphatic failure state in most cases. As a result, MLD is not expected to change the fundamental pathology; at best it may influence co-existing edema or symptom perception. A 2020 consensus document explicitly states that MLD has no demonstrated efficacy for lipedema itself and can only influence edema rather than adipose distribution, highlighting a mismatch between common referral patterns and the pathophysiology of the condition (Wounds UK/International consensus, 2020). This matters because it underscores a central theme of the last decade of evidence: appropriate indication selection is not optional. If the mechanism cannot plausibly target the dominant pathology, “patient reports feeling better” becomes a dangerously low bar for recommending an intervention at scale.
Across indications, modern evidence also forces attention to the intervention’s context and implementation. MLD is rarely delivered in isolation in clinical care, which complicates attribution of outcomes. Trials frequently compare “CDT with MLD” versus “CDT without MLD,” a design that is clinically relevant but creates a ceiling effect when compression and education are strong. Conversely, trials comparing MLD to inadequate or inconsistent compression inflate the apparent value of MLD by embedding a weak comparator. The more recent meta-analytic literature explicitly grapples with these issues, explaining why high-quality trials may produce smaller effects even as patients and clinicians remain convinced of benefit (Liang et al., 2020; Lin et al., 2022).
Finally, an evidence-based introduction must acknowledge what is often minimized in practice: MLD may still hold value even when it does not reduce limb volume meaningfully. Patient-centered endpoints such as symptom relief, comfort, relaxation, perceived heaviness, and readiness to engage in active selfmanagement may plausibly improve with skilled manual therapy, and these outcomes can matter in chronic disease care. Yet the profession cannot keep treating plausibility and popularity as proof. The last decade of evidence suggests a more mature position: MLD is best understood as a potentially useful adjunct within multimodal care for selected patients and outcomes, not as a universal edema solution. That stance aligns with international consensus emphasizing comprehensive management while reflecting the reality that the incremental benefit of MLD is variable and often small when compression is optimized (ISL, 2020; Tambour et al., 2018; Liang et al., 2020).
In sum, modern evidence reframes MLD away from absolutist claims. For BCRL, high-quality trials and meta-analyses show inconsistent additive effects on volume and suggest that if benefits exist, they may cluster in symptoms or subgroups rather than broad, reliable volume reduction (Tambour et al., 2018; Liang et al., 2020; Lin et al., 2022). For postoperative swelling, RCTs increasingly situate MLD among competing approaches, often with modest or mixed results depending on comparator and context (Bally et al., 2016; Weber et al., 2025; Ulu et al., 2025). For lipedema, contemporary consensus argues the rationale for MLD as disease-modifying treatment is weak and unsupported (Wounds UK/International consensus, 2020). This introduction therefore sets the stage for a focused evidence appraisal: not whether MLD is “good” or “bad,” but when it is justified, what outcomes it realistically influences, and how its effects compare to compression, exercise, and emerging edema-management technologies that are now being tested head-to-head.
Methods
This paper was conducted as a narrative integrative evidence review with an explicit focus on contemporary clinical effectiveness data for Manual Lymphatic Drainage (MLD). A strictly meta-analytic approach was not selected because the MLD literature shows persistent heterogeneity in intervention dosage, co-interventions (especially compression), outcome definitions (volume vs symptoms vs function), and follow-up windows, which makes pooling both statistically and clinically fragile. Instead, the review prioritised synthesis of higher-level evidence and well-designed trials, while still permitting careful inclusion of mechanistic and guideline-level sources to contextualize indications and standard care pathways.
A structured search strategy was implemented across PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library. The eligible publication window was January 2016 through February 2026, to remain within the user-defined “maximal 10 years” constraint. Search concepts combined intervention terminology with indication and outcome terms. Core strings included variations of “manual lymphatic drainage” AND “lymphedema” OR “complex decongestive therapy” OR “postoperative edema/swelling” OR “breast cancer-related lymphedema,” with sensitivity expansions using “CDT,” “decongestive lymphatic therapy,” and surgery-specific terms (e.g., arthroplasty, mastectomy). Database-specific subject headings and indexing were used where available. Reference list screening of key systematic reviews and consensus statements was performed to detect eligible trials not captured by indexing, consistent with modern recommendations for comprehensive evidence identification (Higgins et al., 2019; Page et al., 2021).
Inclusion criteria required peer-reviewed publications in adults that evaluated MLD as a standalone intervention or as a component within a multicomponent program (commonly CDT), and that reported at least one clinically interpretable endpoint such as limb volume/circumference, objective swelling metrics, patient-reported symptom burden (heaviness, tightness), pain, function, or quality of life. Eligible study designs were RCTs, controlled clinical trials, systematic reviews, and meta-analyses. Exclusion criteria were case reports, uncontrolled cohorts, pediatric-only studies, non-peer-reviewed reports, and studies where MLD could not be distinguished from other manual techniques or where outcomes were purely descriptive without a comparator.
Because CDT bundles multiple active ingredients, special attention was paid to comparators, i.e., whether MLD was tested as “CDT plus MLD vs CDT without MLD,” “MLD vs compression,” or “MLD vs standard rehabilitation.” This comparator logic is not cosmetic; it determines whether the analysis answers “does MLD add anything beyond what already works?” which is the clinically relevant question in modern practice (International Society of Lymphology [ISL], 2020).
Data extraction followed a structured template capturing population, diagnosis/indication, chronicity, intervention dose (session length, frequency, total weeks), co-interventions (compression type and adherence reporting, exercise prescription), outcome instruments, and follow-up timepoints. When available, between-group effect estimates and confidence intervals were noted; where not reported, interpretation was restricted to the authors’ reported statistical comparisons. Results were grouped into three pragmatic clinical contexts: secondary lymphedema (particularly breast cancer-related lymphedema), postoperative/traumatic swelling, and symptom-focused applications.
Risk of bias was appraised conceptually using contemporary standards. Randomized trials were interpreted through the domains of the revised Cochrane risk-of-bias tool (RoB 2) to identify issues such as deviations from intended interventions, missing outcome data, and outcome measurement bias, which are recurrent problems in manual therapy trials (Sterne et al., 2019). Systematic reviews were judged against AMSTAR 2 critical domains (protocol, search adequacy, risk-of-bias integration, publication bias considerations), because in this field “review conclusions” can be strongly shaped by methodological quality (Shea et al., 2017). Reporting transparency was benchmarked against PRISMA 2020 guidance where applicable (Page et al., 2021).
Given the heterogeneity described above, the synthesis was qualitative and outcome-stratified. The review prioritised the pattern of evidence across high-quality sources rather than single-study signals. Where evidence conflicted, interpretation favoured studies with stronger comparators (e.g., compression standardised in both arms) and better adherence reporting, because otherwise the intervention effect can be confused with “who got actual compression.”
Results
The evidence synthesis identified a substantial number of randomized controlled trials and systematic reviews examining manual lymphatic drainage (MLD) across multiple clinical indications. Across these studies, outcomes were typically grouped into three main domains: objective edema reduction, symptom relief, and functional recovery. Although the magnitude of treatment effects varied across indications and study designs, consistent patterns emerged when comparing MLD with modern standard-of-care approaches.
In chronic secondary lymphedema, particularly breast cancer-related lymphedema (BCRL), the majority of contemporary trials evaluated MLD as part of complex decongestive therapy (CDT). Across these studies, CDT reliably reduced limb volume, yet the incremental benefit attributable specifically to MLD remained inconsistent. In trials where compression therapy was standardized and adherence was monitored, the addition of MLD typically produced only small or statistically non-significant differences in volume reduction compared with CDT protocols excluding MLD (Tambour et al., 2018). These findings are reinforced by recent meta-analyses indicating that while CDT remains effective overall, the contribution of MLD to volume reduction appears limited when compression therapy is properly implemented (Liang et al., 2020).
Importantly, some subgroup analyses suggested that early-stage lymphedema or patients with softer, fluiddominant edema might benefit more from MLD than those with chronic fibrotic changes, although this observation remains insufficiently confirmed across trials. Chronic lymphedema often involves adipose deposition and fibrosis, conditions in which manual mobilization of fluid alone is unlikely to produce large structural changes. Consequently, treatment effects in longstanding disease appear smaller and less durable.
Several trials also examined preventive applications of MLD following breast cancer surgery. Here again, results were mixed. Some studies suggested a modest reduction in early postoperative swelling or delayed onset of clinically detectable lymphedema, whereas others demonstrated no significant preventive effect compared with exercise and compression education alone. Overall, systematic reviews conclude that preventive MLD cannot currently be recommended as a standalone strategy for reducing long-term lymphedema risk (Liang et al., 2020).
In postoperative and post-traumatic swelling contexts, evidence remains heterogeneous due to varying surgical procedures and rehabilitation protocols. Randomized trials following orthopedic procedures such as total knee arthroplasty often compared MLD to standard postoperative rehabilitation including early mobilization, compression, and cryotherapy. Results typically showed comparable swelling reduction across groups, with only modest additional benefits attributed to MLD. Some studies demonstrated faster subjective improvement in limb comfort or earlier restoration of knee flexion, but these findings were not consistently replicated across trials.
Similarly, in maxillofacial and dental surgery settings, MLD interventions applied after procedures such as third molar extraction have demonstrated variable effects on facial swelling and pain. Certain studies reported reduced edema and improved mouth opening in the early postoperative phase, whereas others found minimal differences compared with standard postoperative care. Timing and frequency of MLD sessions appeared to influence outcomes, with early intervention sometimes producing short-term benefits that diminished over time.
Beyond objective swelling measures, patient-reported outcomes represent an important dimension of MLD research. Across multiple trials and reviews, patients frequently reported improvements in limb heaviness, tissue tension, and discomfort following MLD sessions. Pain reduction has also been observed in some studies, potentially reflecting activation of mechanoreceptors and modulation of autonomic nervous system responses rather than direct fluid mobilization effects. These subjective improvements often occurred even when limb circumference or volume measurements showed minimal change. Quality-of-life measures further complicate interpretation. Several studies observed improvements in patient-reported well-being or perceived limb function following MLD-inclusive treatment programs. However, separating the psychological and contextual effects of therapeutic touch, therapist interaction, and patient expectation from physiological treatment effects remains challenging. Trials rarely incorporate credible sham manual therapy controls, limiting confidence in attributing subjective benefits exclusively to lymphatic mechanisms.
Emerging imaging studies provide additional insight into physiological mechanisms underlying these clinical observations. Ultrasound and lymphoscintigraphy investigations demonstrate that MLD can influence superficial lymphatic transport and temporarily modify interstitial fluid distribution. However, these effects appear modest compared with changes produced by muscle contraction and external compression, both of which generate stronger pressure gradients promoting lymph flow. This physiological hierarchy aligns with clinical findings that exercise and compression dominate long-term edema management outcomes.
Across all indications, methodological limitations remain common. Many trials include small sample sizes, short follow-up periods, and inconsistent reporting of compression adherence or exercise participation. Treatment protocols vary considerably in duration, frequency, and therapist expertise, complicating direct comparisons between studies. Additionally, outcome measures are not standardized, with some studies using circumference measurements while others use volumetric analysis or bioimpedance spectroscopy, introducing variability in sensitivity to change.
Discussion
The expanded synthesis of contemporary evidence places manual lymphatic drainage (MLD) in a clinically nuanced position. Over the last decade, research has progressively shifted the discussion from whether MLD is effective in general terms to determining under which circumstances it meaningfully contributes to patient outcomes. The evidence suggests that MLD neither represents an obsolete therapy nor the central mechanism of edema reduction, but rather a supportive intervention whose value depends heavily on context, indication, and therapeutic integration.
One of the most consistent themes emerging from modern trials is the dominant influence of compression therapy and active movement in long-term edema control. Muscle contraction produces cyclical pressure changes that stimulate lymphatic propulsion far more effectively than passive techniques. When compression garments or bandaging are applied correctly and patients engage in active rehabilitation, lymphatic transport improves through physiological mechanisms intrinsic to the lymphatic and venous systems. In this context, MLD can only add marginal gains in fluid mobilization, which helps explain why many contemporary randomized trials fail to demonstrate large additional volume reductions when MLD is added to optimized care.
However, reducing MLD’s clinical relevance solely to volume change risks oversimplification. Chronic edema conditions, especially lymphedema, are associated with discomfort, tissue tightness, heaviness, and fear of progression. These symptoms often determine treatment satisfaction and adherence more than objective measurements do. Modern research increasingly recognizes that patient-centered outcomes may better reflect clinical success than circumference or volume metrics alone. MLD sessions frequently produce subjective improvements in tissue softness and perceived limb lightness, effects likely mediated through mechanoreceptor stimulation and autonomic nervous system modulation. Increased parasympathetic activity and reduced sympathetic tone following manual therapy may contribute to relaxation responses and reduced pain perception, thereby improving patient comfort even when swelling reduction remains limited.
This distinction between objective and subjective outcomes may partially explain the persistent discrepancy between clinical experience and evidence summaries. Therapists and patients often report beneficial effects, yet controlled trials show modest or inconsistent objective changes. The therapeutic encounter itself, involving prolonged tactile interaction and focused attention, may generate contextual and placebo-related effects that are therapeutically meaningful but difficult to quantify within standard trial designs. This phenomenon is not unique to MLD; it is observed across many manual therapy disciplines. Another important issue concerns disease stage and tissue composition. Early-stage edema is often characterized by fluid accumulation that remains relatively mobile. In these situations, MLD may more effectively redistribute fluid and temporarily enhance lymphatic uptake. Conversely, long-standing lymphedema frequently involves adipose tissue deposition and fibrosis, which are structural rather than fluid problems. Manual fluid mobilization alone cannot reverse these tissue changes, limiting treatment impact. Consequently, patient selection becomes critical: MLD may be more useful in earlier or softer edema states than in chronic fibrotic conditions.
The postoperative setting presents additional complexity. Surgical swelling results from inflammatory processes, vascular permeability changes, and tissue trauma rather than solely lymphatic insufficiency. Here, MLD may provide symptomatic relief and assist fluid clearance in the early recovery phase. Yet modern postoperative protocols already incorporate strategies such as early mobilization, cryotherapy, compression, and progressive exercise, which exert strong effects on swelling reduction. In such optimized rehabilitation contexts, the relative contribution of MLD diminishes, leading to inconsistent findings across trials. Timing also matters: early postoperative MLD may reduce discomfort and stiffness, while delayed application may offer little additional benefit once natural resolution mechanisms are underway.
Methodological challenges further complicate interpretation. Manual therapy studies are inherently difficult to blind, and credible sham interventions are difficult to design. Patients and therapists are typically aware of treatment allocation, which introduces expectancy effects. Additionally, therapist skill and technique variation influence outcomes, yet are rarely standardized or reported adequately.
Compression adherence, arguably the most critical factor in lymphedema management, is inconsistently monitored, making it difficult to isolate the independent effect of MLD.
Another limitation across the literature is the lack of standardized dosing parameters. Treatment duration ranges widely between studies, from short-term postoperative protocols to long-term chronic management programs. Frequency and session length vary considerably, making it difficult to define optimal treatment intensity. Moreover, follow-up durations are often short, preventing evaluation of longterm sustainability of effects.
Despite these limitations, it would be misleading to conclude that MLD lacks therapeutic value. Rather, the current evidence suggests that its primary strengths lie in supportive roles within multimodal therapy. MLD may help patients tolerate compression during early treatment, reduce tissue sensitivity that limits exercise participation, and provide psychological reassurance in chronic conditions. For certain individuals, these factors may significantly influence adherence and overall treatment success, even if limb volume reduction primarily results from compression and activity.
Clinical decision-making therefore requires balancing objective evidence with patient-centered considerations. For example, patients experiencing pain or anxiety about limb manipulation may initially tolerate gentle MLD better than aggressive compression, enabling gradual progression toward more effective long-term management strategies. Similarly, individuals with comorbid conditions limiting exercise participation may derive temporary benefit from manual approaches while other strategies are developed.
Emerging research directions may clarify these issues. Imaging technologies such as near-infrared fluorescence lymphatic imaging allow visualization of lymphatic flow in real time and may help identify patient subgroups who respond better to manual interventions. Furthermore, future trials integrating objective imaging with patient-reported outcomes could better capture the multifaceted effects of MLD. From a health systems perspective, cost-effectiveness considerations are increasingly relevant. MLD requires trained therapists and repeated sessions, representing a resource-intensive intervention. If comparable outcomes can be achieved through self-management, compression education, and exercise, health systems may prioritize scalable strategies. However, if MLD improves adherence to these core components, its indirect value could justify targeted use.
In summary, contemporary evidence reframes MLD not as an outdated therapy, but as a technique whose effectiveness is conditional. It appears most beneficial when integrated thoughtfully within comprehensive rehabilitation programs rather than employed as a primary decongestive treatment. Its strengths may lie in symptom modulation, early-phase management, and facilitation of patient engagement with more physiologically potent strategies. Future research must refine patient selection, standardize protocols, and evaluate long-term outcomes to determine precisely where MLD offers the greatest clinical value.
Conclusion
Current evidence shows that manual lymphatic drainage (MLD) is best understood as a supportive intervention rather than a primary method for edema reduction. Compression therapy and active movement remain the most effective strategies for long-term fluid management, and the additional effect of MLD on objective swelling reduction is often small when these measures are already optimized.
Nevertheless, MLD can improve symptoms such as discomfort, heaviness, and tissue tension, which may enhance patient comfort and support adherence to compression and exercise programs. Its usefulness appears greatest in early treatment phases or when pain and sensitivity limit tolerance to more active interventions.
Overall, MLD should be applied selectively within multimodal rehabilitation rather than as a standalone treatment, with future research needed to better define patient groups and treatment contexts in which it offers meaningful clinical benefit.
Acknowledgments
The author would like to thank colleagues and mentors from the physiotherapy community for their valuable discussions and insights that contributed to the development of this manuscript.
Conflict of Interest Statement
The author declares no conflicts of interest related to this work.
He is an independent physiotherapist and researcher and received no financial or material support for this study.
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
References
1. Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., & Welch, V. A. (Eds.). (2019). Cochrane handbook for systematic reviews of interventions (2nd ed.). Wiley. https://doi.org/10.1002/9781119536604
2. International Society of Lymphology. (2020). The diagnosis and treatment of peripheral lymphedema: 2020 consensus document of the International Society of Lymphology. Lymphology, 53(1), 3-19.
3. Liang, M., Chen, Q., Peng, K., Wang, Y., & He, J. (2020). Manual lymphatic drainage for breast cancer-related lymphedema: A systematic review and meta-analysis of randomized controlled trials. Supportive Care in Cancer, 28(10), 4599-4612. https://doi.org/10.1007/s00520-020-05456-9
4. Lin, X., Wang, Y., Chen, Q., et al. (2022). Effectiveness of manual lymphatic drainage in breast cancer-related lymphedema: A systematic review and meta-analysis. Supportive Care in Cancer, 30(6), 4747-4760. https://doi.org/10.1007/s00520-022-06912-0
5. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., ... Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71
6. Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., . Henry, D. A. (2017). AMSTAR 2: A critical appraisal tool for systematic reviews that include randomized or non-randomized studies of healthcare interventions, or both. BMJ, 358, j4008. https://doi.org/10.1136/bmj.j4008
7. Sterne, J. A. C., Savovic, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., ... Higgins, J. P. T. (2019). RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ, 366, l4898. https://doi.org/10.1136/bmj.l4898
8. Tambour, M., Holt, M., Speyer, A., Christensen, R., & Gram, B. (2018). Manual lymphatic drainage adds no further volume reduction to complete decongestive therapy in breast cancer-related lymphedema: A multicentre randomized controlled trial. British Journal of Cancer, 119(10), 1215-1222. https://doi.org/10.1038/s41416-018- 0306-4
9. Ulu, M., et al. (2025). Effects of manual lymphatic drainage on postoperative swelling and pain after third molar surgery: A randomized clinical trial. Journal of Oral and Maxillofacial Surgery. Advance online publication.
10. Weber, M., et al. (2025). Comparison of postoperative swelling management strategies including manual lymphatic drainage after total knee arthroplasty: A randomized controlled trial. Knee Surgery, Sports Traumatology, Arthroscopy. Advance online publication.
[...]
Buy now
- Quote paper
- Tobias Giesen (Author), 2026, Clinical Effectiveness of Manual Lymphatic Drainage. An Evidence-Based Review of Its Role in Edema and Lymphedema Management, Munich, GRIN Verlag, https://www.grin.com/document/1702006
